Last reviewed · How we verify
Insulin aspart 6 day reservoir in-use
Insulin aspart 6 day reservoir in-use is a Rapid-acting insulin analog Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 3 development for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.
Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin aspart 6 day reservoir in-use |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin aspart is a recombinant human insulin analog with a rapid onset and short duration of action. It mimics the body's natural insulin response to meals by binding to insulin receptors on muscle and fat cells, promoting glucose uptake and storage while suppressing hepatic glucose production. The 6-day reservoir formulation extends the duration of action compared to standard insulin aspart, allowing for less frequent dosing.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use (PHASE3)
- Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin aspart 6 day reservoir in-use CI brief — competitive landscape report
- Insulin aspart 6 day reservoir in-use updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Insulin aspart 6 day reservoir in-use
What is Insulin aspart 6 day reservoir in-use?
How does Insulin aspart 6 day reservoir in-use work?
What is Insulin aspart 6 day reservoir in-use used for?
Who makes Insulin aspart 6 day reservoir in-use?
What drug class is Insulin aspart 6 day reservoir in-use in?
What development phase is Insulin aspart 6 day reservoir in-use in?
What are the side effects of Insulin aspart 6 day reservoir in-use?
What does Insulin aspart 6 day reservoir in-use target?
Related
- Drug class: All Rapid-acting insulin analog drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Eli Lilly and Company — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: Insulin aspart 6 day reservoir in-use vs similar drugs
- Pricing: Insulin aspart 6 day reservoir in-use cost, discount & access